Bobby Sheng, Bora Pharmaceuticals CEO
Taiwan-based CDMO Bora Pharma to pay up to $210M for Upsher-Smith to expand into the US
Taiwan-headquartered CDMO Bora Pharmaceuticals is buying generic manufacturer Upsher-Smith Laboratories for up to $210 million to expand operations into the US for the first time …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.